Your browser doesn't support javascript.
loading
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken, M G; Leeneman, B; Aarts, M J B; van Akkooi, A C J; van den Berkmortel, F W P J; Boers-Sonderen, M J; van den Eertwegh, A J M; de Groot, J W B; Hospers, G A P; Kapiteijn, E; Piersma, D; van Rijn, R S; Suijkerbuijk, K P M; van der Veldt, A A M; Westgeest, H M; Wouters, M W J M; Haanen, J B A G; Uyl-de Groot, C A.
Affiliation
  • Franken MG; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: franken@imta.eur.nl.
  • Leeneman B; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
  • Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
  • de Groot JWB; Oncology Center Isala, Isala, Zwolle, The Netherlands.
  • Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
  • Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Piersma D; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
  • van Rijn RS; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
  • Suijkerbuijk KPM; Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.
  • van der Veldt AAM; Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
  • Wouters MWJM; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Uyl-de Groot CA; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
ESMO Open ; 6(6): 100320, 2021 12.
Article in En | MEDLINE | ID: mdl-34856511
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Type of study: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma Type of study: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article